http://www.fpnotebook.com/
Third Generation Broad-Spectrum CephalosporinsAka: Third Generation Cephalosporins, Ceftriaxone, Ceftizoxime, Cefotaxime, Cefpodoxime, Cefixime, Claforan, Rocephin, Vantin
- See Also
- Coverage:
- Gram Positive Cocci
- Less activity than First Generation Cephalosporins
- EKP Gram Negative Bacteria
- ESP Gram Negative Bacteria
- Better activity than First Generation Cephalosporins
- Better activity than Second Generation Cephalosporins
- No Pseudomonas activity
- Gram Positive Cocci
- Oral agents
- Cefixime (Suprax)
- Adult
- Standard: 400 mg PO divided qd to bid
- Gonorrhea: 400 mg PO for single dose
- Child: 8 mg/kg/day divided qd to bid
- Adult
- Cefpodoxime (Vantin)
- Good activity Gram Positive organisms
- Covers Staphylococcus aureus
- Covers Pneumococcus
- Adult: 100 to 400 mg PO bid
- Child
- Pharyngitis: 10 mg/kg/day divided bid
- Otitis Media: 10 mg/kg/day divided qd
- Good activity Gram Positive organisms
- Cefixime (Suprax)
- Parenteral agents
- Cefotaxime (Claforan)
- Most Staphylococcus aureus and Anaerobic activity
- Adult: 1 to 2 grams IM or IV every 6 to 8 hours
- Child
- Standard: 50-150 mg/kg/day IM or IV divided q4-6h
- Meningitis: 200 mg/kg/day IV divided q6-8h
- Maximum dose: 2 grams
- Ceftizoxime (Cefizox)
- Moderate Staphylococcus aureus and Anaerobic Activity
- Adult: 1 to 2 grams IV every 8 to 12 hours
- Child: 50 mg/kg/dose IV every 6 to 8 hours
- Ceftriaxone (Rocephin)
- Least Staphylococcus and Anaerobic activity
- Dilute in Lidocaine 1% for Intramuscular Injection
- Adult
- Standard: 1-2 grams IM or IV every 24 hours
- Gonorrhea: 125 mg IM single dose
- Child
- Standard: 50-75 mg/kg/day IV divide q12-24 hours
- Meningitis: 100 mg/kg/day IV divided q12-24 hours
- Otitis Media: 50 mg/kg IM single dose (max: 1g)
- Maximum Dose: 2 grams (4 grams for Meningitis)
- Cefotaxime (Claforan)
Cefotaxime (C0007554) | |
|---|---|
| Definition (MSH) | Semisynthetic broad-spectrum cephalosporin. |
| Definition (PDQ) | A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39177&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39177&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C354" NCI Thesaurus) |
| Definition (NCI) | A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. |
| Concepts | Organic Chemical (T109) , Antibiotic (T195) |
| MSH | D002439 |
| English | Cefotaxim, Cefotaxime, CEFOTAXIME PREPARATION, Cefotaxime product, Cephotaxim |
| Spanish | cefotaxima |
| Parent Concepts | Cephacetrile (C0007714), Cephalosporins (C0007732), Third generation cephalosporin (C0304320) |
| Sources | LNC, MSH, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Ceftizoxime (C0007560) | |
|---|---|
| Definition (MSH) | A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. |
| Concepts | Organic Chemical (T109) , Antibiotic (T195) |
| MSH | D015296 |
| English | Ceftizoxime, CEFTIZOXIME PREPARATION |
| Spanish | ceftizoxima |
| Parent Concepts | Cefotaxime (C0007554), Cephalosporins (C0007732), Third generation cephalosporin (C0304320) |
| Sources | LNC, MSH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Rocephin (C0035750) | |
|---|---|
| Concepts | Organic Chemical (T109) , Antibiotic (T195) |
| MSH | D002443 |
| English | Hoffman La Roche Brand of Ceftriaxone Sodium, Hoffman-La Roche Brand of Ceftriaxone Sodium, Rocefalin, Rocefin, Rocephin, Rocephine, Roche Brand of Ceftriaxone Sodium |
| Sources | MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
cefpodoxime (C0055011) | |
|---|---|
| Definition (NCI) | A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation. |
| Concepts | Organic Chemical (T109) , Antibiotic (T195) |
| MSH | C053268 |
| English | cefpodoxime, CEFPODOXIME PREPARATION |
| Spanish | cefpodoxima |
| Parent Concepts | Cephalosporins (C0007732), Third generation cephalosporin (C0304320) |
| Sources | LNC, MSH, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG Derived from the NIH UMLS (Unified Medical Language System) |
Cefixime (C0060400) | |
|---|---|
| Definition (MSH) | A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases. |
| Definition (PDQ) | A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37809&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37809&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1100" NCI Thesaurus) |
| Definition (NCI) | A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins. |
| Concepts | Organic Chemical (T109) , Antibiotic (T195) |
| MSH | D020682 |
| English | Cefixime, CEFIXIME PREPARATION |
| Spanish | cefixima |
| Parent Concepts | Cefotaxime (C0007554), Cephalosporins (C0007732), Third generation cephalosporin (C0304320) |
| Sources | LNC, MSH, MTH, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Claforan (C0701052) | |
|---|---|
| Concepts | Organic Chemical (T109) , Antibiotic (T195) |
| MSH | D002439 |
| English | Aventis Brand of Cefotaxime Sodium, Aventis Pharma Brand of Cefotaxime Sodium, Claforan, Hoechst Brand of Cefotaxime Sodium, Klaforan, Primafen |
| Sources | MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
Vantin (C0724204) | |
|---|---|
| Concepts | Organic Chemical (T109) , Antibiotic (T195) |
| MSH | C053267 |
| English | Vantin |
| Sources | MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
